UNH Stock: Buy or Sell? Price Target & Forecast

Analyses / UNH

UNH UnitedHealth Group Inc As of Jul 3, 2026

$425.36

Large-cap healthcare leader: premium valuation, strong insider support, but near 52-week highs with slowing earnings.

Setup: quality_consolidation Confidence: 68 Horizon: 3-6 months Risk: medium Category: Large-cap

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals UNH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Diversified healthcare giant with 11.35% revenue growth and insider net buying (104 buys vs 26 sells). Dividend yield 2.18% + buyback support. Congress members accumulating. Stock up 81% from 52-week low ($234.60), signaling institutional confidence. May consolidate and push higher if earnings stabilize.

▼ Bear Case

EPS down 14.51% YoY despite 11% revenue growth—margin compression risk. Forward P/E 32.3x not cheap for a 2.69% net margin operator. Current ratio 0.89 signals tight working capital. At 52-week high; limited margin of safety. Payout ratio 65.66% leaves little room for unexpected headwinds.

Valuation

fair_to_slightly_overvalued — score 62/100

P/E 32.3x and forward P/E 32.3x are elevated for a 2.69% net margin business. P/S 0.87x is reasonable for a large-cap, but price-to-FCF 24.8x signals premium pricing. EV/EBITDA 19x is steep given earnings headwinds.

Technical Levels

Support · $420.54 (Today's low) · $410.00 (Psychological round) · $395.00 (Stop loss target) · $375.00 (52-week low cushion (within range))

Resistance · $430.20 (52-week high / today's high) · $440.00 (Psychological round) · $450.00 (3-month target)

Financial Health

Score 70/100. Current ratio 0.89 is below 1.0—tight working capital, though typical for large insurers with negative cash conversion cycles. Quick ratio 0.67 also tight. Dividend payout 65.66% is sustainable. Book value and revenue per share are solid. Beta 0.63 indicates lower-than-market volatility.

Catalysts

Q2 earnings report (expected ~July 2024)	Next 4-6 weeks	High—EPS trend and margin outlook will reset valuation. Any stabilization or beat could push to $450+; miss could trigger $400 test.
Federal insurance policy / drug pricing regulation updates	Ongoing	Medium—changes to Medicare/MLR rules could alter profitability. Positive reforms (e.g., lower rebate caps) could be tailwinds.
Dividend / share buyback announcements	Q2-Q3 earnings calls	Medium—capital return increases would reinforce income appeal and share count reduction.
Competitor earnings (e.g., Cigna, Aetna/CVS, Anthem)	Next 2-4 weeks	Medium—sector-wide margin and growth trends will set UNH narrative.

Risk Flags

EPS declining 14.51% YoY despite revenue growth—earnings quality concern.

Current ratio 0.89 below 1.0—working capital tightness; monitor liquidity.

Trading near 52-week highs with limited downside cushion below $395.

Net margin 2.69% is thin for a $386B market cap; vulnerable to cost pressures.

See UNH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock UNH free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

UNH FAQ

Is UNH a buy right now?

UnitedHealth Group Inc's current read is a quality_consolidation setup with 68 confidence over a 3-6 months horizon. Valuation: fair_to_slightly_overvalued. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is UNH overvalued?

fair_to_slightly_overvalued (valuation score 62/100). P/E 32.3x and forward P/E 32.3x are elevated for a 2.69% net margin business. P/S 0.87x is reasonable for a large-cap, but price-to-FCF 24.8x signals premium pricing. EV/EBITDA 19x is steep given earnings headwinds.

What are the risks of buying UNH?